1st Counsel – Lifestyle
Author:
Septerna, Inc.
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
April 13, 2026
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
March 9, 2026